

Article

# Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System

Roozbeh Nayerhoda <sup>1</sup>, Andrew Hill <sup>2,3</sup>, Marie Beitelshoes <sup>2</sup>, Charles Jones <sup>3,\*</sup> and Blaine Pfeifer <sup>1,2,\*</sup>


<sup>1</sup> Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA

<sup>2</sup> Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA


<sup>3</sup> Abcombi Biosciences Inc., 1576 Sweet Home Road, Amherst, NY 14228, USA

\* Correspondence: charles.jones@abcombibio.com (C.J.); blainepf@buffalo.edu (B.P.)


## Supplementary Materials:




**Figure S1.** Liposomal formation schematic featuring initiation (A) and extrusion (B).



**Figure S2.** Liposomal purification and protein surface labeling (with GFP, in this case), proceeding from steps A to D.



**Figure S3.** Assay for polysaccharide quantification. (A) Absorbance maximum for the polysaccharide 19F used in the quantification of encapsulation efficiency assays. (B) Colorimetric assay solution development pre- and post-incubation (blank and standard solutions are shown in triplicate and additional wells represent various samples tested within this particular assay).



**Figure S4.** Purification process for the NTA-cobalt liposomal variant featuring purified liposomes (A), liposomes post-extrusion (B), and free polysaccharide (C). Sample analysis was performed using the assay for polysaccharide assessment.